Literature DB >> 14602756

Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study.

P Szulc1, B Claustrat, F Marchand, P D Delmas.   

Abstract

The goal of this study was to identify the clinical and biological patterns of hypogonadism in a cohort of 1040 elderly men. Residual androgenic activity was estimated by total testosterone as well as the apparent free testosterone concentration (AFTC) and free testosterone index (FTI) calculated on the basis of concentrations of SHBG and total testosterone using appropriate formulae. The lower limit of the normal range defined by 2 SD below the mean in 150 healthy, nonobese, and nonsmoking men, aged 19-40 yr, was calculated for total testosterone (9.26 nmol/liter), AFTC (146 pmol/liter), and FTI (0.14 nmol/nmol). The prevalence of hypogonadism increased with ageing. Hypogonadal men were older and heavier (due to a higher fat body mass) and had lower concentrations of 17 beta-estradiol and androstenedione than men with normal androgenic activity. Men with decreased AFTC had a slightly lower bone mineral density (BMD) at certain sites. Men with decreased FTI had lower appendicular skeletal muscle mass and relative skeletal muscle index. For all three measures of androgenic activity, hypogonadal men had increased levels of the markers of bone resorption. In the multiple regression models including both 17 beta-estradiol and testosterone (total, AFTC, or FTI), 17 beta-estradiol was the only significant determinant of BMD. In the multiple regression models including 17 beta-estradiol and AFTC or FTI, only testosterone was a significant determinant of the variability in bone formation markers, whereas both 17 beta-estradiol and testosterone were significant determinants of the variability of the markers of bone resorption. Hypogonadism was associated with an increase in the risk of falls, an impairment of static and dynamic balance, as well as the inability to stand up from a chair and to perform the tandem walk. Decreased AFTC (<146 pmol/liter) discriminated best men with functional disabilities (odds ratio, 1.54-7.95; P < 0.05-0.0001). Hypogonadal elderly men had increased bone resorption that was not adequately matched by an increase in bone formation, lower muscle strength, impaired static and dynamic balance, a higher risk of falls, and, in men with low AFTC, a slightly lower BMD. Low AFTC seems to have the best discriminative power for densitometric, biochemical, and functional parameters, followed by FTI, whereas total testosterone was the least discriminative. In multiple regression models, 17 beta-estradiol was the strongest determinant of BMD, and AFTC and FTI were significant determinants of the variability in bone formation markers, whereas both 17 beta-estradiol and testosterone determined the variability in bone resorption markers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14602756     DOI: 10.1210/jc.2003-030200

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  37 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Graded inhibition of pulsatile luteinizing hormone secretion by a selective gonadotropin-releasing hormone (GnRH)-receptor antagonist in healthy men: evidence that age attenuates hypothalamic GnRH outflow.

Authors:  Paul Y Takahashi; Peter Y Liu; Pamela D Roebuck; Ali Iranmanesh; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

3.  Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate.

Authors:  K Kayan; H Johansson; A Oden; S Vasireddy; K Pande; J Orgee; J A Kanis; E V McCloskey
Journal:  Osteoporos Int       Date:  2009-05-13       Impact factor: 4.507

4.  Administration of saccharin to neonatal mice influences body composition of adult males and reduces body weight of females.

Authors:  Sebastian D Parlee; Becky R Simon; Erica L Scheller; Emilyn U Alejandro; Brian S Learman; Venkatesh Krishnan; Ernesto Bernal-Mizrachi; Ormond A MacDougald
Journal:  Endocrinology       Date:  2014-01-23       Impact factor: 4.736

5.  Novel strategies for improving physical function.

Authors:  Shalender Bhasin; Ravi Jasuja; Powen Tu; Thomas W Storer; Wen Guo
Journal:  Horm Res Paediatr       Date:  2011-07-21       Impact factor: 2.852

Review 6.  Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Thomas W Storer; Renee Miciek; Thomas G Travison
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

7.  CYP19A1 polymorphisms are associated with bone mineral density in Chinese men.

Authors:  Xiumei Hong; Yi-Hsiang Hsu; Henry Terwedow; Lester M Arguelles; Genfu Tang; Xue Liu; Shanchun Zhang; Xin Xu; Xiping Xu
Journal:  Hum Genet       Date:  2007-01-11       Impact factor: 4.132

8.  Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study.

Authors:  Joanne B Krasnoff; Shehzad Basaria; Michael J Pencina; Guneet K Jasuja; Ramachandran S Vasan; Jagadish Ulloor; Anqi Zhang; Andrea Coviello; Margaret Kelly-Hayes; Ralph B D'Agostino; Philip A Wolf; Shalender Bhasin; Joanne M Murabito
Journal:  J Clin Endocrinol Metab       Date:  2010-04-09       Impact factor: 5.958

Review 9.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

Review 10.  The many faces of testosterone.

Authors:  Jerald Bain
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.